Loading...
ASX Announcements 2020-10-06T20:23:19-05:00

October 2020

  • Medibio Submits Request For FDA Breakthrough Device Designation

View ASX Announcement

  • Medibio Signs Clinical Trial Agreement With US-based MedBridge Healthcare LLC For its Depressive Burden Trial

View ASX Announcement

September 2020

  • Medibio Limited – Annual Report – 30 June 2020

View ASX Announcement

  • Corporate Governance Council Principles and Recommendations

View ASX Announcement

  • Corporate Governance Statement – 2020

View ASX Announcement

August 2020

  • FDA Strategy and Regulatory Update 

View ASX Announcement

  • Medibio granted US Patent for Monitoring Stress Conditions Using Heartrate

View ASX Announcement

  • Appendix 2A Application for quotation of & securities

View ASX Announcement

  • Appendix 4E Preliminary Final Report 30 June 2020

View ASX Announcement

  • FDA Strategy & Regulatory Update

View ASX Announcement

July 2020

  • Medibio Announces Entitlement Issue Results

View ASX Announcement

  • Appendix 2A Application for quotation of + securities

View ASX Announcement

  • Appendix 3Y Change of Director’s Interest Notice

View ASX Announcement

  • June Quarterly Activities Report and Appendix 4C

View ASX Announcement

June 2020

  • Appendix 2A Application for quotation of +securities

View ASX Announcement

  • Appendix 3G Notification of issue, conversion or payment up of equity +securities

View ASX Announcement

  • MEB Raises $2m via Placement and Fully Underwritten Entitlement Offer

View ASX Announcement

  • Offer Document Entitlement Issue

View ASX Announcement

  • Non-Renounceable Entitlement Offer Cleansing Notice under Section 708AA(2)(F) of the Corporations Act 2001 (Cth)

View ASX Announcement

  • Section 708A Cleansing Notice

View ASX Announcement

  • Investor Presentation 

View ASX Announcement

  • Notification to ineligible shareholders of Entitlement Offer

View ASX Announcement

  • Notification of pro-rata non-renounceable Entitlement Issue

View ASX Announcement

  • Notification to eligible shareholders of Entitlement Offer

View ASX Announcement

  • Section 708A Cleansing Notice and Appendix 2A

View ASX Announcement

  • Despatch of Offer Letter to Eligible Shareholders

View ASX Announcement

  • Appendix 3G Notification of issue, conversion or payment up of equity +securities

View ASX Announcement

  • MEB Announces Extension to Entitlement Offer

View ASX Announcement

May 2020

  • Medibio Settles Joint Venture Dispute

View ASX Announcement

Announcement Summary

April 2020

  • Medibio’s ilumen™ supporting the global workforce during  COVID-19 health crisis

View ASX Announcement

  • Final Compass Pilot completed successfully

View ASX Announcement

  • Capital Structure Update

View ASX Announcement

  • Medibio Submits FDA 510K Application to the FDA for its Sleep Staging Medical Software Device

View ASX Announcement

  • Quarterly Activities Report and Appendix 4C

View ASX Announcement

March 2020

  • Executive Appointments at Medibio to Support Growth of ilumen™

View ASX Announcement

  • FDA Strategy Update

View ASX Announcement

  • Medibio Signs Memorandum of Understanding with DXC for ilumen™

View ASX Announcement

February 2020

  • Strategic Plan for FDA and CE Mark Approval 

View ASX Announcement

  • Medibio Signs Annual Services Agreement with Stantec Australia for ilumen™ 

View ASX Announcement

  • Appendix 4D and Half-Yearly Report for 31 December 2019

View ASX Announcement

January 2020

  • Changes to the Board

View ASX Announcement

  • Final Director’s Interest Notice

View ASX Announcement

  • Letter from the Managing Director

View ASX Announcement

  • Quarterly Operations Report and Appendix 

View ASX Announcement

December 2019

  • Report to Shareholders and Outlook for 2020 

View ASX Announcement

  • Appendix 3G:  Notification of issue, conversion or payment up of equity +securities

View ASX Announcement

  • Appendix 3Y: Change of Director’s Interest Notice

View ASX Announcement

November 2019

  • Results of Annual General Meeting 

View ASX Announcement

  • Company Update 

View ASX Announcement

  • Final Directors Interest Notice 

View ASX Announcement

October 2019

  • Medibio Provides Updated Securities Trading Policy

View ASX Announcement

  • Medibio Successfully Completes First Pilot with Compass Group

View ASX Announcement

  • Medibio Notice of Annual General Meeting and Proxy Form

View ASX Announcement

  • Notice of Ceasing to be a Substantial Holder

Save View ASX Announcement

  • Medibio CEO to Participate on Panel at Garmin Digital Health Summit APAC

View ASX Announcement

  • Medibio Signs Agreement with PwC Australia for ilumen

View ASX Announcement

  • Quarterly Update and Appendix 4C 31 October 2019

View ASX Announcement

September 2019

  • Withdrawal of Notice of Initial Substantial Shareholding

View ASX Announcement

  • Becoming A Substantial Holder 2 Sept 2019

View ASX Announcement

  • Change in Substantial Holding 3 Sept 2019

View ASX Announcement

  • Cleansing Notice 4 September 2019

View ASX Announcement

  • Change of Directors Interest  4 Sept 2019

View ASX Announcement

  • Initial Directors Interest 4 Sept 2019

View ASX Announcement

  • Medibio Announces Results of Review of Partly Paid Shares

View ASX Announcement

  • Medibio Appendix 4G and Governance Statement

View ASX Announcement

  • Medibio 2019 Annual Report

View ASX Announcement

August 2019

  • Medibio Supplementary Prospectus

View ASX Announcement

  • Medibio Results of August 2019 AGM

View ASX Announcement

  • Medibio Appendix 3B 20 August 2019

View ASX Announcement

  • Medibio Completes Oversubscribed Share Purchase Plan

View ASX Announcement

  • Medibio ASX Information for New Quoted Option Class

View ASX Announcement

  • Medibio Appendix 3B 29 August 2019

View ASX Announcement

  • Medibio Announces New Board Members and Establishes Growth & Advocacy Advisory Board 

View ASX Announcement

  • Medibio Announces Fourth Pilot Agreement with Compass Group 

View ASX Announcement

  • Medibio Appendix 4E Preliminary Report

View ASX Announcement

  • Medibio Becoming a Substantial Holder 30 Aug 2019

View ASX Announcement

  • Medibio Appendix 3B 30 Aug 2019

View ASX Announcement

  • Medibio Final Directors Notice 30 Aug 2019

View ASX Announcement

July 2019

  • Medibio Signs Global Organisation, Compass Group PLC, for the First of Two UK-based Pilots for ilumen™

View ASX Announcement

  • Medibio Requests Trading Halt in Relation to Capital Raising

View ASX Announcement

  • Medibio Suspension from Official Quotation

View ASX Announcement

  • Medibio Reinstatement to Official Quotation

View ASX Announcement

  • Medibio Raises $4,020,000 By Way of a Placement and Fully Underwritten SPP

View ASX Announcement

  • Medibio Signs Second Compass Group PLC Pilot for ilumen™

View ASX Announcement

  • Medibio Notice of Extraordinary General Meeting, Explanatory Statement and Proxy Form

View ASX Announcement

  • Medibio Notice of Change of Interest of Substantial Holder

View ASX Announcement

  • Medibio Prospectus Offer of Options and Shares for SPP

View ASX Announcement

  • Medibio Appendix 3B

View ASX Announcement

  • Medibio Partners with Digital Corporate Wellness Solution Leader WellteQ

View ASX Announcement

  • Medibio Signs Compass Group Australia for Corporate Health Product ilumen™

View ASX Announcement

  • Medibio Quarterly Operations Report and Appendix 4C

View ASX Announcement

June 2019

  • Appendix 3B New Issue Announcement

View ASX Announcement

  • Joint Venture Dispute

View ASX Announcement

  • Change of Directors Notice 

View ASX Announcement

  • Medibio Algorithm Validated in Study Published in Peer Reviewed Journal 

View ASX Announcement

May 2019

  • Medibio Provides Updated Investor Deck

View ASX Announcement

  • Medibio Results of General Meeting

View ASX Announcement

  • Medibio Response to ASX 4C Query

View ASX Announcement

  • Medibio Provides Updated Investor Deck 27 May 2019

View ASX Announcement

April 2019

  • Medibio Provides Notice of General Meeting

View ASX Announcement

  • Medibio Announces Sponsored Research Agreement with Humanitas

View ASX Announcement

  • Medibio Announces Revised Regulatory and Commercialisation Strategy

View ASX Announcement

  • Medibio Provides Quarterly Message and Appendix 4C

View ASX Announcement

March 2019

  • Medibio Corporate Health Product ilumen™ Successfully Completes First Commercial Program

View ASX Announcement

  • Medibio Announces Entitlement Issue Results and Shortfall Notification

View ASX Announcement

  • Medibio Outsources Psychology Services in Support of Corporate Health Product ilumen™

View ASX Announcement

  • Medibio Announces Completion of Entitlement Issue

View ASX Announcement

  • Medibio Shareholder Update & Outlook

View ASX Announcement

  • Medibio Provides Updated Investor Presentation

View ASX Announcement

February 2019

  • Medibio Extension of Entitlement Offering

View ASX Announcement

  • Medibio Investor Presentation 

View ASX Announcement

  • Medibio Announces Changes to Board of Directors and Appointment of Chairman

View ASX Announcement

  • Medibio Announces Extension to Entitlement Offer

View ASX Announcement

  • Medibio Correction to Extension of Entitlement Offer

View ASX Announcement

  • Medibio Appendix 4D Half Year Report

View ASX Announcement

January 2019

  • Medibio Results of January 2019 General Meeting

View ASX Announcement

  • Medibio Cleansing Notice and Appendix 3B

View ASX Announcement

  • Medibio Quarterly Update & Cash Flow

View ASX Announcement

December 2018

  • Medibio Requests Trading Halt

View ASX Announcement

  • Medibio Converting Note & Non-Renounceable Entitlement Offer

    View ASX Announcement

  • Medibio Section 708AA(2)(F) Cleansing Statement and Appendix 3B

View ASX Announcement

  • Medibio Updated Investor Presentation December 10, 2018

View ASX Announcement

View ASX Announcement

  • Medibio Notice of  General Meeting

    View ASX Announcement

  • Medibio Announces Changes to the Board of Directors and Cost Reduction Plans

View ASX Announcement

November 2018

  • Medibio Market Update

View ASX Announcement

  • Medibio Appoints Global Healthcare & Medical Device Leader as CEO and Managing Director

View ASX Announcement

  • Medibio Provides Update on FDA Process

View ASX Announcement

View ASX Announcement

October 2018

  • Notice Received Under Section 249D of the Corporations Act

View ASX Announcement

  • Medibio Releases Corporate Health Product, ilumen™

View ASX Announcement

  • Medibio Updates Company Presentation

View ASX Announcement

  • Medibio Technology Honored with Two Presentations at Mayo Clinic Convergence Neuroscience 2018

View ASX Announcement

View ASX Announcement

  • Medibio Quarterly & Cash Flow Report

View ASX Announcement

September 2018

  • Medibio Clinical Study Shows Over 20% Improvement to Current Diagnostic Standard

View ASX Announcement

  • Medibio Hosts Call to Discuss Clinical Validation Study

View ASX Announcement

  • Medibio Market Update

View ASX Announcement

  • Medibio Releases Appendix 4G & Corporate Governance Statement

View ASX Announcement

  • Medibio Releases Financial Report for the Year Ended 30 June 2018

View ASX Announcement

  • Medibio Announces Executive Leadership Changes

View ASX Announcement

August 2018

  • Medibio announces change in senior management 

View ASX Announcement

July 2018

  • Medibio Submits FDA De Novo Application

View ASX Announcement

  • Medibio to announce fourth quarter FY18 results

View ASX Announcement

  • Quarterly Update and Message from CEO of Medibio Limited

View ASX Announcement

June 2018

  • Appointment and Resignation of Company Secretary And Change of Registered Office Address

View Press Release PDF

  • Medibio provides updated Investor Presentation

View Press Release PDF

  • Medibio to Provide Corporate Health Investor Presentation

View Press Release PDF

  • Medibio Receives TGA Approval

View Press Release PDF

  • Peer-reviewed Neurology Publication on Medibio Science

View ASX Announcement

May 2018

  • Medibio Announces Global Launch – Corporate Mental Health For Business

View Press Release PDF

  • Medibio Receives CE Certification

View Press Release PDF

  • Medibio Corporate Health contract signed with Australia’s 3rd largest private healthcare provider

View Press Release PDF

  • Medibio Launches Personal Mental Health Measurement App for Apple Watch

View Press Release PDF

  • Medibio Announces Next Tranche of Corporate Health Contracts

View Press Release PDF

  • Medibio Corporate Health Signs Global Contract with Jacobs Engineering

View Press Release PDF

April 2018

  • Medibio finalizes acquisition of Vital Conversations

View Press Release PDF

  • Medibio Announces Scientific Advisory Board

View Press Release PDF

  • Medibio to announce third Quarter FY18 update and cashflow

View Announcement

  • Quarterly ASX Update and Cashflows

View Announcement

January 2018

  • Peter Carlisle Appointed as Director

View Press Release PDF

  • Medibio Investor Conference Call Announcement
    • Australia – 1st February
    • U.S. – January 31st

December 2017

  • U.S. Department of Veterans Affairs White River Junction Medical Center Joins Medibio Depression Diagnostic Confirmatory Study to Support FDA Clearance

View Press Release PDF

  • Mayo Clinic to begin Prospective Clinical Study with Medibio Technology for Expanded Market Opportunities

View Press Release PDF

November 2017

  • Medibio Annual General Meeting Materials

Download Presentation PDF

Watch Videos

October 2017

August 2017

July 2017

June 2017

May 2017

April 2017

March 2017

February 2017

January 2017

December 2016

November 2016

October 2016

September 2016

August 2016

July 2016

June 2016

May 2016

April 2016

March 2016

February 2016

January 2016

December 2015

November 2015

October 2015

September 2015

August 2015

July 2015

May 2015

April 2015

March 2015

February 2015

January 2015

Archived Announcements